Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

St. John's wort

This article was originally published in The Tan Sheet

Executive Summary

Flawed endpoints, study design, analysis by Vanderbilt researchers in St. John's wort/depression trial charged by researchers, consultants, CRN reps in letters to the editor appearing in July 4 Journal of the American Medical Association. Trial by Richard Shelton, MD, et al., Vanderbilt University Medical Center, which found botanical to have no advantage over placebo for major depression, was published in April 18 JAMA (1"The Tan Sheet" April 23, p. 10). Shelton et al. defend their study protocol, saying "the simple placebo-controlled trial is a widely accepted design," and note their article conceded possible efficacy of herbal in treating mild-to-moderate depression

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092774

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel